TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01694784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Study: NCT03724903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ductal lavage
Description: The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
Study: NCT01694784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framed Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Study: NCT03730285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Installation of videotelephone with broadband in patient's home
Study: NCT04000620

Intervention type: PROCEDURE
Intervention: surgery
Description: treatment intent surgery

Intervention type: PROCEDURE
Intervention: surgery
Description: treatment intent surgery

Intervention type: PROCEDURE
Intervention: punture
Description: diagnostic punture

Intervention type: PROCEDURE
Intervention: punture
Description: diagnostic punture
Study: NCT01646190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Carbohydrate load
Description: oral intake in the evening before surgery and 2-3h before intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individualized i.v fluids therapy
Description: by Transoesophageal aortic US-Doppler done intraoperatively

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting state after midnight
Description: No preoperative glucose load

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Nasogastric tube postoperatively
Description: Withdrawal after complete awakening in operating room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: urinary catheter removal
Description: at POD 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral liquids
Description: 0.3-0.5L oral liquids at 6h postoperatively on POD 0

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation of inspirex utilization
Description: using 6-8 times/day to prevent pulmonary atelectasis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), \>4h out of bed on POD1, \>6h on POD2, complete at POD3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preanesthetic medication
Description: Preanesthetic oral medication before surgery
Study: NCT00049036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03513497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized acrylic mouthguard
Description: Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized acrylic mouthguard
Description: Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
Study: NCT01164943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with human FSH
Description: Human FSH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with recombinant FSH
Description: Recombinant FSH
Study: NCT03724903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid therapy
Description: Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
Study: NCT02989246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator protocol
Description: Open loop ventilator management by a computer based protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Catheter
Description: Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
Study: NCT01080118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq
Description: Subjects were taught with the Airtraq video laryngoscope

Intervention type: OTHER
Group type: OTHER
Intervention: Control group, taught with a standard Macintosh laryngoscope
Description: Subjects were taught how to use the Mackintosh blade first
Study: NCT00419848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Cap 100mg- 100mg/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
Study: NCT05410405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant site preparation
Description: piezoelectric bone surgery osseodensification drills

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant site preparation
Description: piezoelectric bone surgery osseodensification drills
Study: NCT02800967

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pure Aronia juice
Description: Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia juice-based beverage
Description: Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
Study: NCT02527252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy
Study: NCT02800967

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
Study: NCT04334239

Intervention type: OTHER
Intervention: Oncological certification
Description: Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
Study: NCT00229957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Study: NCT01960985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physicaltherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physicaltherapy
Study: NCT03551197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and formoterol bid
Description: At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
Study: NCT01837719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300-mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300-mg capsule
Study: NCT00229957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management
Study: NCT03852849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal involved intervention strategies
Description: Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The dosage of 400mg EFV
Description: The dosage of 400mg EFV will be used in the antiviral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The dosage of 400mg EFV
Description: The dosage of 400mg EFV will be used in the antiviral therapy.
Study: NCT02527252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Massage
Study: NCT02661269

Intervention type: DEVICE
Intervention: Videomicroscopy of the sublingual microcirculation
Description: Measuring total vessel density with the Cytocam-IDF camera.

Intervention type: DEVICE
Intervention: Videomicroscopy of the sublingual microcirculation
Description: Measuring total vessel density with the Cytocam-IDF camera.

Intervention type: DEVICE
Intervention: Bio-impedance measurements.
Description: measuring resistance and reactance with the BIVA method.

Intervention type: DEVICE
Intervention: Bio-impedance measurements.
Description: measuring resistance and reactance with the BIVA method.
Study: NCT03477201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic robotic DaVinci assisted inguinal hernia repair
Description: Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic inguinal hernia repair
Description: Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
Study: NCT01938430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily
Study: NCT01837719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: 150-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: 150-mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat FDC
Description: Atazanavir 300-mg/cobicistat 150-mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat FDC
Description: Atazanavir 300-mg/cobicistat 150-mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat FDC
Description: Atazanavir 300-mg/cobicistat 150-mg FDC tablet
Study: NCT03606850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of markers of cortical excitability by TMS
Description: In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle.
Study: NCT01162564

Intervention type: DEVICE
Intervention: NG-TSM
Description: Flexible Composite Next Generation Tissue Separating Mesh
Study: NCT03326050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemifloxacin
Description: Gemifloxacin 320Mg Oral Tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemifloxacin
Description: Gemifloxacin 320Mg Oral Tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemifloxacin
Description: Gemifloxacin 320Mg Oral Tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: cipro 750 tablet twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: cipro 750 tablet twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: cipro 750 tablet twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150Mg Capsule twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150Mg Capsule twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150Mg Capsule twice daily
Study: NCT01995318

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesiotaping
Description: Application of anti-edema type kinesiotaping to injured ankle.
Study: NCT01938430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose
Study: NCT02887430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology therapy
Description: standard care and foot reflexology
Study: NCT00674570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 25 mg/oral one hour prior to extinction task

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg/oral one hour prior to extinction task

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One hour prior to extinction task
Study: NCT03472456

Intervention type: DRUG
Intervention: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne

Intervention type: DRUG
Intervention: Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
Study: NCT02228395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in treatment arm
Study: NCT04203043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pycnogenol Oral Product
Description: pycnogenol use to prevent hyper pigmentation after foam sclerotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02426723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1a: CWP232291
Description: CWP232291 administered alone twice weekly every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1b: CWP232291, Lenalidomide, Dexamethasone
Description: CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
Study: NCT02953743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.